Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



We're Still Buying. Probably.

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

We're trying to buy it. We're definitely buying it. We're buying it, but only if nothing else bad happens.

Johnson & Johnson (NYSE: JNJ  ) has run the gamut of emotions in its potential marriage to vaccine maker Crucell (Nasdaq: CRXL  ) over the last few months.

In September, the duo said they were in talks to complete a buyout. Normally these things would just remain behind closed doors until final details were worked out, but Dutch law seems to require Crucell to make the announcement. It did the same thing when it was in talks with Wyeth. That potential deal fell through when Pfizer (NYSE: PFE  ) bought Wyeth.

Less than a month later, the deal terms between J&J and Crucell had been worked out, and the two just needed to wait for antitrust authorities to sign off on the deal.

Or so it seemed. At the end of October, Crucell said it was stopping shipments of two vaccines because of a microbiological contamination at its plant in Korea.

Johnson & Johnson has decided that the problem isn't big enough to derail the deal. Manufacturing at the plant should be back up and running by February, so Johnson & Johnson will commence its acquisition of the shares it doesn't already own before Dec. 10.

Management at Johnson & Johnson probably knows what it's getting itself into -- the company had already owned nearly 18% of Crucell even before the talks began -- but I have to wonder whether Johnson & Johnson really needs the headache. Inheriting a manufacturing issue on top of all the manufacturing problems it already has doesn't seem like the best idea.

Johnson & Johnson said the manufacturing interruption didn't constitute a "material adverse effect" that would have allowed it to break the deal, but this seems to be a gray area that could be exploited if it wanted to. Why not negotiate for better deal terms like it did with Elan (NYSE: ELN  ) to get a better deal after Biogen Idec (Nasdaq: BIIB  ) balked? At the very least, negotiating would allow Johnson & Johnson to buy some time and see if the manufacturing problems could be fixed as quickly as Crucell says they can.

Johnson & Johnson did leave open the possibility of breaking the deal if anything else comes to light before the offer is completed. Perhaps the plan is to stall between when it initiates the offer to buy the outstanding shares and when it finally closes the sale.

Investors may not have seen the end of this dragged-out engagement.

Toby Shute goes value shopping in a picked-over market.

Motley Fool Options has recommended a diagonal call position on Johnson & Johnson, which is a Motley Fool Income Investor selection. Pfizer is a Motley Fool Inside Value recommendation. Elan is a Motley Fool Rule Breakers selection. The Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1385990, ~/Articles/ArticleHandler.aspx, 10/28/2016 2:16:21 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,111.44 -58.24 -0.32%
S&P 500 2,122.60 -10.44 -0.49%
NASD 5,188.15 -27.82 -0.53%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/28/2016 2:00 PM
BIIB $283.33 Down -7.56 -2.60%
Biogen CAPS Rating: *****
CRXLY.DL $0.00 Down +0.00 +0.00%
Crucell N.V. (ADR) CAPS Rating: **
ELN.DL2 $0.00 Down +0.00 +0.00%
Elan CAPS Rating: ***
JNJ $115.11 Down -0.59 -0.51%
Johnson and Johnso… CAPS Rating: *****
PFE $32.00 Down -0.48 -1.47%
Pfizer CAPS Rating: ****